Click for best price
Chronic Pulmonary Hypertension Drug Market Size, Share 2024
The global Chronic Pulmonary Hypertension Drug market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is to reach $ Million.
Oral Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Chronic Pulmonary Hypertension Drug include Bayer, Attgeno, Cereno Scientific, Bial - Portela C S.A, Liquidia Technologies, Bellerophon Therapeutics, AbbVie Therapeutics, Insmed and Altavant Sciences, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
Pulmonary hypertension?happens when the pressure in the blood vessels leading from the heart to the lungs is too high. With pulmonary hypertension, the blood vessels to the lungs develop an increased amount of muscle in the wall of the blood vessels.
This report aims to provide a comprehensive presentation of the global market for Chronic Pulmonary Hypertension Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Pulmonary Hypertension Drug. This report contains market size and forecasts of Chronic Pulmonary Hypertension Drug in global, including the following market information:
Global Chronic Pulmonary Hypertension Drug Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global top five companies in 2023 (%)
We surveyed the Chronic Pulmonary Hypertension Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Chronic Pulmonary Hypertension Drug Market, by Type, 2019-2024, 2025-2030 ($ millions)
Global Chronic Pulmonary Hypertension Drug Market Segment Percentages, by Type, 2023 (%)
Oral
Intravenous/Subcutaneous
Inhalational
Global Chronic Pulmonary Hypertension Drug Market, by Application, 2019-2024, 2025-2030 ($ millions)
Global Chronic Pulmonary Hypertension Drug Market Segment Percentages, by Application, 2023 (%)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Chronic Pulmonary Hypertension Drug Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions)
Global Chronic Pulmonary Hypertension Drug Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Chronic Pulmonary Hypertension Drug revenues in global market, 2019-2024 (estimated), ($ millions)
Key companies Chronic Pulmonary Hypertension Drug revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer
Attgeno
Cereno Scientific
Bial - Portela C S.A
Liquidia Technologies
Bellerophon Therapeutics
AbbVie Therapeutics
Insmed
Altavant Sciences
Lupin
Sun Pharmaceutical
Teva
Outline of Major Chapters:
Chapter 1: Introduces the definition of Chronic Pulmonary Hypertension Drug, market overview.
Chapter 2: Global Chronic Pulmonary Hypertension Drug market size in revenue.
Chapter 3: Detailed analysis of Chronic Pulmonary Hypertension Drug company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Chronic Pulmonary Hypertension Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Chronic Pulmonary Hypertension Drug Market, Global Outlook and Forecast 2024-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
67 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Chronic Pulmonary Hypertension Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Chronic Pulmonary Hypertension Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Chronic Pulmonary Hypertension Drug Overall Market Size
2.1 Global Chronic Pulmonary Hypertension Drug Market Size: 2023 VS 2030
2.2 Global Chronic Pulmonary Hypertension Drug Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Chronic Pulmonary Hypertension Drug Players in Global Market
3.2 Top Global Chronic Pulmonary Hypertension Drug Companies Ranked by Revenue
3.3 Global Chronic Pulmonary Hypertension Drug Revenue by Companies
3.4 Top 3 and Top 5 Chronic Pulmonary Hypertension Drug Companies in Global Market, by Revenue in 2023
3.5 Global Companies Chronic Pulmonary Hypertension Drug Product Type
3.6 Tier 1, Tier 2 and Tier 3 Chronic Pulmonary Hypertension Drug Players in Global Market
3.6.1 List of Global Tier 1 Chronic Pulmonary Hypertension Drug Companies
3.6.2 List of Global Tier 2 and Tier 3 Chronic Pulmonary Hypertension Drug Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Chronic Pulmonary Hypertension Drug Market Size Markets, 2023 & 2030
4.1.2 Oral
4.1.3 Intravenous/Subcutaneous
4.1.4 Inhalational
4.2 By Type - Global Chronic Pulmonary Hypertension Drug Revenue & Forecasts
4.2.1 By Type - Global Chronic Pulmonary Hypertension Drug Revenue, 2019-2024
4.2.2 By Type - Global Chronic Pulmonary Hypertension Drug Revenue, 2025-2030
4.2.3 By Type - Global Chronic Pulmonary Hypertension Drug Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Chronic Pulmonary Hypertension Drug Market Size, 2023 & 2030
5.1.2 Hospital Pharmacy
5.1.3 Retail Pharmacy
5.1.4 Online Pharmacy
5.2 By Application - Global Chronic Pulmonary Hypertension Drug Revenue & Forecasts
5.2.1 By Application - Global Chronic Pulmonary Hypertension Drug Revenue, 2019-2024
5.2.2 By Application - Global Chronic Pulmonary Hypertension Drug Revenue, 2025-2030
5.2.3 By Application - Global Chronic Pulmonary Hypertension Drug Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Chronic Pulmonary Hypertension Drug Market Size, 2023 & 2030
6.2 By Region - Global Chronic Pulmonary Hypertension Drug Revenue & Forecasts
6.2.1 By Region - Global Chronic Pulmonary Hypertension Drug Revenue, 2019-2024
6.2.2 By Region - Global Chronic Pulmonary Hypertension Drug Revenue, 2025-2030
6.2.3 By Region - Global Chronic Pulmonary Hypertension Drug Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Chronic Pulmonary Hypertension Drug Revenue, 2019-2030
6.3.2 US Chronic Pulmonary Hypertension Drug Market Size, 2019-2030
6.3.3 Canada Chronic Pulmonary Hypertension Drug Market Size, 2019-2030
6.3.4 Mexico Chronic Pulmonary Hypertension Drug Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Chronic Pulmonary Hypertension Drug Revenue, 2019-2030
6.4.2 Germany Chronic Pulmonary Hypertension Drug Market Size, 2019-2030
6.4.3 France Chronic Pulmonary Hypertension Drug Market Size, 2019-2030
6.4.4 U.K. Chronic Pulmonary Hypertension Drug Market Size, 2019-2030
6.4.5 Italy Chronic Pulmonary Hypertension Drug Market Size, 2019-2030
6.4.6 Russia Chronic Pulmonary Hypertension Drug Market Size, 2019-2030
6.4.7 Nordic Countries Chronic Pulmonary Hypertension Drug Market Size, 2019-2030
6.4.8 Benelux Chronic Pulmonary Hypertension Drug Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Chronic Pulmonary Hypertension Drug Revenue, 2019-2030
6.5.2 China Chronic Pulmonary Hypertension Drug Market Size, 2019-2030
6.5.3 Japan Chronic Pulmonary Hypertension Drug Market Size, 2019-2030
6.5.4 South Korea Chronic Pulmonary Hypertension Drug Market Size, 2019-2030
6.5.5 Southeast Asia Chronic Pulmonary Hypertension Drug Market Size, 2019-2030
6.5.6 India Chronic Pulmonary Hypertension Drug Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Chronic Pulmonary Hypertension Drug Revenue, 2019-2030
6.6.2 Brazil Chronic Pulmonary Hypertension Drug Market Size, 2019-2030
6.6.3 Argentina Chronic Pulmonary Hypertension Drug Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Chronic Pulmonary Hypertension Drug Revenue, 2019-2030
6.7.2 Turkey Chronic Pulmonary Hypertension Drug Market Size, 2019-2030
6.7.3 Israel Chronic Pulmonary Hypertension Drug Market Size, 2019-2030
6.7.4 Saudi Arabia Chronic Pulmonary Hypertension Drug Market Size, 2019-2030
6.7.5 UAE Chronic Pulmonary Hypertension Drug Market Size, 2019-2030
7 Chronic Pulmonary Hypertension Drug Companies Profiles
7.1 Bayer
7.1.1 Bayer Company Summary
7.1.2 Bayer Business Overview
7.1.3 Bayer Chronic Pulmonary Hypertension Drug Major Product Offerings
7.1.4 Bayer Chronic Pulmonary Hypertension Drug Revenue in Global Market (2019-2024)
7.1.5 Bayer Key News & Latest Developments
7.2 Attgeno
7.2.1 Attgeno Company Summary
7.2.2 Attgeno Business Overview
7.2.3 Attgeno Chronic Pulmonary Hypertension Drug Major Product Offerings
7.2.4 Attgeno Chronic Pulmonary Hypertension Drug Revenue in Global Market (2019-2024)
7.2.5 Attgeno Key News & Latest Developments
7.3 Cereno Scientific
7.3.1 Cereno Scientific Company Summary
7.3.2 Cereno Scientific Business Overview
7.3.3 Cereno Scientific Chronic Pulmonary Hypertension Drug Major Product Offerings
7.3.4 Cereno Scientific Chronic Pulmonary Hypertension Drug Revenue in Global Market (2019-2024)
7.3.5 Cereno Scientific Key News & Latest Developments
7.4 Bial - Portela C S.A
7.4.1 Bial - Portela C S.A Company Summary
7.4.2 Bial - Portela C S.A Business Overview
7.4.3 Bial - Portela C S.A Chronic Pulmonary Hypertension Drug Major Product Offerings
7.4.4 Bial - Portela C S.A Chronic Pulmonary Hypertension Drug Revenue in Global Market (2019-2024)
7.4.5 Bial - Portela C S.A Key News & Latest Developments
7.5 Liquidia Technologies
7.5.1 Liquidia Technologies Company Summary
7.5.2 Liquidia Technologies Business Overview
7.5.3 Liquidia Technologies Chronic Pulmonary Hypertension Drug Major Product Offerings
7.5.4 Liquidia Technologies Chronic Pulmonary Hypertension Drug Revenue in Global Market (2019-2024)
7.5.5 Liquidia Technologies Key News & Latest Developments
7.6 Bellerophon Therapeutics
7.6.1 Bellerophon Therapeutics Company Summary
7.6.2 Bellerophon Therapeutics Business Overview
7.6.3 Bellerophon Therapeutics Chronic Pulmonary Hypertension Drug Major Product Offerings
7.6.4 Bellerophon Therapeutics Chronic Pulmonary Hypertension Drug Revenue in Global Market (2019-2024)
7.6.5 Bellerophon Therapeutics Key News & Latest Developments
7.7 AbbVie Therapeutics
7.7.1 AbbVie Therapeutics Company Summary
7.7.2 AbbVie Therapeutics Business Overview
7.7.3 AbbVie Therapeutics Chronic Pulmonary Hypertension Drug Major Product Offerings
7.7.4 AbbVie Therapeutics Chronic Pulmonary Hypertension Drug Revenue in Global Market (2019-2024)
7.7.5 AbbVie Therapeutics Key News & Latest Developments
7.8 Insmed
7.8.1 Insmed Company Summary
7.8.2 Insmed Business Overview
7.8.3 Insmed Chronic Pulmonary Hypertension Drug Major Product Offerings
7.8.4 Insmed Chronic Pulmonary Hypertension Drug Revenue in Global Market (2019-2024)
7.8.5 Insmed Key News & Latest Developments
7.9 Altavant Sciences
7.9.1 Altavant Sciences Company Summary
7.9.2 Altavant Sciences Business Overview
7.9.3 Altavant Sciences Chronic Pulmonary Hypertension Drug Major Product Offerings
7.9.4 Altavant Sciences Chronic Pulmonary Hypertension Drug Revenue in Global Market (2019-2024)
7.9.5 Altavant Sciences Key News & Latest Developments
7.10 Lupin
7.10.1 Lupin Company Summary
7.10.2 Lupin Business Overview
7.10.3 Lupin Chronic Pulmonary Hypertension Drug Major Product Offerings
7.10.4 Lupin Chronic Pulmonary Hypertension Drug Revenue in Global Market (2019-2024)
7.10.5 Lupin Key News & Latest Developments
7.11 Sun Pharmaceutical
7.11.1 Sun Pharmaceutical Company Summary
7.11.2 Sun Pharmaceutical Business Overview
7.11.3 Sun Pharmaceutical Chronic Pulmonary Hypertension Drug Major Product Offerings
7.11.4 Sun Pharmaceutical Chronic Pulmonary Hypertension Drug Revenue in Global Market (2019-2024)
7.11.5 Sun Pharmaceutical Key News & Latest Developments
7.12 Teva
7.12.1 Teva Company Summary
7.12.2 Teva Business Overview
7.12.3 Teva Chronic Pulmonary Hypertension Drug Major Product Offerings
7.12.4 Teva Chronic Pulmonary Hypertension Drug Revenue in Global Market (2019-2024)
7.12.5 Teva Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Chronic Pulmonary Hypertension Drug Market Opportunities & Trends in Global Market
Table 2. Chronic Pulmonary Hypertension Drug Market Drivers in Global Market
Table 3. Chronic Pulmonary Hypertension Drug Market Restraints in Global Market
Table 4. Key Players of Chronic Pulmonary Hypertension Drug in Global Market
Table 5. Top Chronic Pulmonary Hypertension Drug Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Chronic Pulmonary Hypertension Drug Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Chronic Pulmonary Hypertension Drug Revenue Share by Companies, 2019-2024
Table 8. Global Companies Chronic Pulmonary Hypertension Drug Product Type
Table 9. List of Global Tier 1 Chronic Pulmonary Hypertension Drug Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Chronic Pulmonary Hypertension Drug Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Chronic Pulmonary Hypertension Drug Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Chronic Pulmonary Hypertension Drug Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Chronic Pulmonary Hypertension Drug Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Chronic Pulmonary Hypertension Drug Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Chronic Pulmonary Hypertension Drug Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Chronic Pulmonary Hypertension Drug Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2025-2030
Table 30. Bayer Company Summary
Table 31. Bayer Chronic Pulmonary Hypertension Drug Product Offerings
Table 32. Bayer Chronic Pulmonary Hypertension Drug Revenue (US$, Mn) & (2019-2024)
Table 33. Bayer Key News & Latest Developments
Table 34. Attgeno Company Summary
Table 35. Attgeno Chronic Pulmonary Hypertension Drug Product Offerings
Table 36. Attgeno Chronic Pulmonary Hypertension Drug Revenue (US$, Mn) & (2019-2024)
Table 37. Attgeno Key News & Latest Developments
Table 38. Cereno Scientific Company Summary
Table 39. Cereno Scientific Chronic Pulmonary Hypertension Drug Product Offerings
Table 40. Cereno Scientific Chronic Pulmonary Hypertension Drug Revenue (US$, Mn) & (2019-2024)
Table 41. Cereno Scientific Key News & Latest Developments
Table 42. Bial - Portela C S.A Company Summary
Table 43. Bial - Portela C S.A Chronic Pulmonary Hypertension Drug Product Offerings
Table 44. Bial - Portela C S.A Chronic Pulmonary Hypertension Drug Revenue (US$, Mn) & (2019-2024)
Table 45. Bial - Portela C S.A Key News & Latest Developments
Table 46. Liquidia Technologies Company Summary
Table 47. Liquidia Technologies Chronic Pulmonary Hypertension Drug Product Offerings
Table 48. Liquidia Technologies Chronic Pulmonary Hypertension Drug Revenue (US$, Mn) & (2019-2024)
Table 49. Liquidia Technologies Key News & Latest Developments
Table 50. Bellerophon Therapeutics Company Summary
Table 51. Bellerophon Therapeutics Chronic Pulmonary Hypertension Drug Product Offerings
Table 52. Bellerophon Therapeutics Chronic Pulmonary Hypertension Drug Revenue (US$, Mn) & (2019-2024)
Table 53. Bellerophon Therapeutics Key News & Latest Developments
Table 54. AbbVie Therapeutics Company Summary
Table 55. AbbVie Therapeutics Chronic Pulmonary Hypertension Drug Product Offerings
Table 56. AbbVie Therapeutics Chronic Pulmonary Hypertension Drug Revenue (US$, Mn) & (2019-2024)
Table 57. AbbVie Therapeutics Key News & Latest Developments
Table 58. Insmed Company Summary
Table 59. Insmed Chronic Pulmonary Hypertension Drug Product Offerings
Table 60. Insmed Chronic Pulmonary Hypertension Drug Revenue (US$, Mn) & (2019-2024)
Table 61. Insmed Key News & Latest Developments
Table 62. Altavant Sciences Company Summary
Table 63. Altavant Sciences Chronic Pulmonary Hypertension Drug Product Offerings
Table 64. Altavant Sciences Chronic Pulmonary Hypertension Drug Revenue (US$, Mn) & (2019-2024)
Table 65. Altavant Sciences Key News & Latest Developments
Table 66. Lupin Company Summary
Table 67. Lupin Chronic Pulmonary Hypertension Drug Product Offerings
Table 68. Lupin Chronic Pulmonary Hypertension Drug Revenue (US$, Mn) & (2019-2024)
Table 69. Lupin Key News & Latest Developments
Table 70. Sun Pharmaceutical Company Summary
Table 71. Sun Pharmaceutical Chronic Pulmonary Hypertension Drug Product Offerings
Table 72. Sun Pharmaceutical Chronic Pulmonary Hypertension Drug Revenue (US$, Mn) & (2019-2024)
Table 73. Sun Pharmaceutical Key News & Latest Developments
Table 74. Teva Company Summary
Table 75. Teva Chronic Pulmonary Hypertension Drug Product Offerings
Table 76. Teva Chronic Pulmonary Hypertension Drug Revenue (US$, Mn) & (2019-2024)
Table 77. Teva Key News & Latest Developments
List of Figures
Figure 1. Chronic Pulmonary Hypertension Drug Segment by Type in 2023
Figure 2. Chronic Pulmonary Hypertension Drug Segment by Application in 2023
Figure 3. Global Chronic Pulmonary Hypertension Drug Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Chronic Pulmonary Hypertension Drug Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Chronic Pulmonary Hypertension Drug Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Chronic Pulmonary Hypertension Drug Revenue in 2023
Figure 8. By Type - Global Chronic Pulmonary Hypertension Drug Revenue Market Share, 2019-2030
Figure 9. By Application - Global Chronic Pulmonary Hypertension Drug Revenue Market Share, 2019-2030
Figure 10. By Type - Global Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Chronic Pulmonary Hypertension Drug Revenue Market Share, 2019-2030
Figure 12. By Application - Global Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Chronic Pulmonary Hypertension Drug Revenue Market Share, 2019-2030
Figure 14. By Region - Global Chronic Pulmonary Hypertension Drug Revenue Market Share, 2019-2030
Figure 15. By Country - North America Chronic Pulmonary Hypertension Drug Revenue Market Share, 2019-2030
Figure 16. US Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Chronic Pulmonary Hypertension Drug Revenue Market Share, 2019-2030
Figure 20. Germany Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2030
Figure 21. France Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Chronic Pulmonary Hypertension Drug Revenue Market Share, 2019-2030
Figure 28. China Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2030
Figure 32. India Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Chronic Pulmonary Hypertension Drug Revenue Market Share, 2019-2030
Figure 34. Brazil Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Chronic Pulmonary Hypertension Drug Revenue Market Share, 2019-2030
Figure 37. Turkey Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Chronic Pulmonary Hypertension Drug Revenue, (US$, Mn), 2019-2030
Figure 41. Bayer Chronic Pulmonary Hypertension Drug Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Attgeno Chronic Pulmonary Hypertension Drug Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. Cereno Scientific Chronic Pulmonary Hypertension Drug Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Bial - Portela C S.A Chronic Pulmonary Hypertension Drug Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. Liquidia Technologies Chronic Pulmonary Hypertension Drug Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Bellerophon Therapeutics Chronic Pulmonary Hypertension Drug Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. AbbVie Therapeutics Chronic Pulmonary Hypertension Drug Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. Insmed Chronic Pulmonary Hypertension Drug Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. Altavant Sciences Chronic Pulmonary Hypertension Drug Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. Lupin Chronic Pulmonary Hypertension Drug Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 51. Sun Pharmaceutical Chronic Pulmonary Hypertension Drug Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 52. Teva Chronic Pulmonary Hypertension Drug Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
